ImmunOs

<!-- Name:DistributionId Value:1000805915 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area),…

- Former Novartis director brings significant expertise in drug discovery and development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 17, 2022 – ImmunOs…

- Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 4, 2022 – ImmunOs…

- New investors Samsara, Lightspeed, Gimv, and Mission BioCapital further strengthen investor base and expand transatlantic footprint - Company establishes U.S. subsidiary to…

- Samsara, Lightspeed, Gimv und Mission BioCapital stärken als neue Anteilseigner das Investorenkonsortium und erweitern die transatlantische Präsenz - Unternehmen gründet…

- L’entrée au capital de Samsara, Lightspeed, Gimv et Mission BioCapital renforce le panel d'investisseurs de la société et lui permet d’asseoir sa présence outre-Atlantique - La…

- Promising data presented at Society for Immunotherapy of Cancer 36th Annual Meeting (SITC) - Multi-functional agent targeting three innate immune checkpoint receptors  - Potential as…

- Preclinical data highlighting mode-of-action of lead program iosH2 Schlieren (Zurich Area), Switzerland. – October 13, 2021 – ImmunOs Therapeutics AG, a Swiss biotechnology company…